Feed KRRO
KR

Korro Bio, Inc.

KRRO · NASDAQ

$14.07 +1.44% (+$0.20)
1M +7.08%
Market Cap $140.0M
P/E Ratio -
Div. Yield -
ROE 114.26%
Piotroski F-Score Weak
2/9
Valuation
50 /100
Fair
P/B 1.36x
P/S 58.79x
EV/EBITDA N/A
Growth
-
N/A
Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak
Net margin 4,477.08%
Op. margin 3,176.57%
FCF margin 2,865.87%
Quality
0 /100
Poor
ROE 114.26%
ROA 65.25%
Asset turnover 0.01x
Debt
94 /100
Low
Current ratio 9.55x
Debt/Equity 0.41x
Net debt/EBITDA N/A
Stability
9 /100
Unstable
EPS volatility 65.13%
Profitable years 0
Beta 2.25x

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about KRRO
Online

About the company

Korro Bio, Inc. (KORO) is an American biotechnology company focused on developing innovative therapeutic approaches in the field of gene therapy and gene editing. With the goal of treating genetic diseases and other complex illnesses using advanced CRISPR technologies and gene editing, Korro Bio is a key player in the biomedicine sector. The company develops therapeutics aimed at modifying the genetic code, which may lead to new treatment options for patients. Korro Bio collaborates with leading scientific institutions and pharmaceutical companies to accelerate the development and commercialization of its products. Korro Bio, Inc. (KORO) shares could be suitable for investors looking to invest in biotechnology with potential for revolutionary advancements in treating genetic diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

Ram Aiyar

Employees

57

Headquarters

Cambridge

Upcoming events

11 NOV

Earnings

Upcoming earnings report

56d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.